Connor Clark & Lunn Investment Management Ltd. Sells 1,775 Shares of argenx SE – (ARGX)

Connor Clark & Lunn Investment Management Ltd. reduced its stake in shares of argenx SE – (NASDAQ:ARGX) by 3.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 55,600 shares of the company’s stock after selling 1,775 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in argenx were worth $6,941,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of argenx during the first quarter valued at about $217,000. BB Biotech AG grew its stake in shares of argenx by 20.4% during the fourth quarter. BB Biotech AG now owns 884,739 shares of the company’s stock valued at $84,997,000 after buying an additional 150,000 shares during the last quarter. Oberweis Asset Management Inc. bought a new position in shares of argenx during the fourth quarter valued at about $27,659,000. Bellevue Group AG bought a new position in shares of argenx during the fourth quarter valued at about $1,210,000. Finally, FNY Investment Advisers LLC bought a new position in shares of argenx during the first quarter valued at about $374,000. 65.68% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ ARGX opened at $137.38 on Friday. The stock has a market capitalization of $4.42 billion, a P/E ratio of -58.46 and a beta of 1.12. argenx SE – has a 1 year low of $63.81 and a 1 year high of $137.50.



ARGX has been the topic of a number of recent research reports. Zacks Investment Research cut argenx from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Stifel Nicolaus reaffirmed a “buy” rating on shares of argenx in a research note on Monday, February 4th. Piper Jaffray Companies raised their price objective on argenx from $161.00 to $182.00 and gave the company an “overweight” rating in a research note on Thursday. Wedbush raised their price objective on argenx from $131.00 to $144.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Finally, Guggenheim began coverage on argenx in a research note on Friday, February 22nd. They issued a “buy” rating and a $157.00 target price on the stock. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. argenx presently has an average rating of “Buy” and an average target price of $147.55.

COPYRIGHT VIOLATION WARNING: This report was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://dakotafinancialnews.com/2019/05/25/connor-clark-lunn-investment-management-ltd-sells-1775-shares-of-argenx-se-argx.html.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Further Reading: What is Forex?

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.